[go: up one dir, main page]

AR054806A1 - Formulaciones de estrogenos conjugados y bazedoxifeno - Google Patents

Formulaciones de estrogenos conjugados y bazedoxifeno

Info

Publication number
AR054806A1
AR054806A1 ARP060102789A ARP060102789A AR054806A1 AR 054806 A1 AR054806 A1 AR 054806A1 AR P060102789 A ARP060102789 A AR P060102789A AR P060102789 A ARP060102789 A AR P060102789A AR 054806 A1 AR054806 A1 AR 054806A1
Authority
AR
Argentina
Prior art keywords
core
bazedoxifene
conjugated estrogens
conjugated
strogens
Prior art date
Application number
ARP060102789A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37401610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054806(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR054806A1 publication Critical patent/AR054806A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Formulaciones de dosificacion solidas conteniendo estrogenos conjugados y bazedoxifeno, o una sal de ellos. En algunas modalidades las composiciones incluyen un nucleo comprende estrogenos conjugados y a lo menos una cobertura que comprende bazedoxifeno o una sal de ellos. Reivindicacion 31: Un proceso para la preparacion de una composicion farmacéutica, caracterizada porque comprende: un nucleo comprende estrogenos conjugados; y una primera cobertura comprende bazedoxifeno o una sal farmacéuticamente aceptable de estos; el proceso comprende: i) proveer un nucleo comprende estrogenos conjugados; y ii) cubrir el nucleo con una composicion comprende bazedoxifeno o una sal farmacéuticamente aceptable de estos para formar un nucleo cubierto.
ARP060102789A 2005-06-29 2006-06-28 Formulaciones de estrogenos conjugados y bazedoxifeno AR054806A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69488905P 2005-06-29 2005-06-29

Publications (1)

Publication Number Publication Date
AR054806A1 true AR054806A1 (es) 2007-07-18

Family

ID=37401610

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102789A AR054806A1 (es) 2005-06-29 2006-06-28 Formulaciones de estrogenos conjugados y bazedoxifeno

Country Status (19)

Country Link
US (1) US20070003623A1 (es)
EP (1) EP1898888A2 (es)
JP (1) JP2008545012A (es)
KR (1) KR20080031037A (es)
CN (1) CN101252921A (es)
AR (1) AR054806A1 (es)
AU (1) AU2006263638A1 (es)
BR (1) BRPI0612586A2 (es)
CA (1) CA2613102A1 (es)
CR (1) CR9597A (es)
EC (1) ECSP078057A (es)
IL (1) IL188223A0 (es)
NI (1) NI200700331A (es)
NO (1) NO20080002L (es)
PA (1) PA8684501A1 (es)
PE (1) PE20070188A1 (es)
RU (1) RU2395286C2 (es)
TW (1) TW200738283A (es)
WO (1) WO2007002823A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8629301A1 (es) * 2004-04-08 2006-10-13 Wyeth Corp Formulaciones de acetato de bezedoxifeno
BRPI0719675A2 (pt) * 2006-11-29 2013-12-24 Wyeth Corp Comprimido com bicamada de estrogênio/serm e estrogênio/progestina
MX2009007254A (es) * 2007-01-12 2009-08-12 Wyeth Corp Composiciones de tableta en tableta.
PE20090100A1 (es) * 2007-03-30 2009-02-26 Wyeth Corp Metodos de separacion y deteccion de acetato de bacedoxifeno en composiciones farmaceuticas
AR078785A1 (es) * 2009-10-27 2011-11-30 Wyeth Llc Formulaciones de bazedoxifeno con antioxidantes
WO2011131943A2 (en) * 2010-04-20 2011-10-27 Cipla Limited Pharmaceutical compositions
CN103119878B (zh) * 2010-07-29 2016-11-16 熵通信有限公司 用于消除交叉极化干扰和交叉卫星干扰的方法和装置
WO2012158030A2 (en) * 2011-05-13 2012-11-22 Emotional Brain B.V. Drug delivery system
CN104013630B (zh) * 2014-05-23 2018-08-21 合肥九研医药科技开发有限公司 一种复方醋酸巴多昔芬雌激素组合物
CN107787224A (zh) 2015-06-18 2018-03-09 密特拉制药公司 含雌四醇组分的口腔分散剂量单位
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
WO2018182205A1 (ko) * 2017-03-30 2018-10-04 한미약품 주식회사 바제독시펜 아세테이트를 함유하는 안정화된 약제학적 조성물
JOP20200260A1 (ar) * 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) * 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2565115A (en) * 1948-10-28 1951-08-21 Squibb & Sons Inc Method of obtaining a conjugated estrogen preparation
US2720483A (en) * 1951-02-21 1955-10-11 Olin Mathieson Method of obtaining a conjugatedestrogen preparation
US5210081A (en) * 1992-02-26 1993-05-11 American Home Products Corporation Alkali metal 8,9-dehydroestrone sulfate esters
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
TR200403328T2 (tr) * 1999-07-06 2005-03-21 Endorecherche, Inc. Kilo alımını tedavi ve/veya önleme metotları.
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
AU2003248707A1 (en) * 2002-06-13 2003-12-31 Wyeth Bazedoxifene treatment regimens
US7683051B2 (en) * 2004-04-07 2010-03-23 Wyeth Crystalline polymorph of bazedoxifene acetate
PA8629201A1 (es) * 2004-04-07 2005-11-25 Wyeth Corp Polimorfo cristalino de acetato de bazedoxifeno
PA8629301A1 (es) * 2004-04-08 2006-10-13 Wyeth Corp Formulaciones de acetato de bezedoxifeno
MXPA06011686A (es) * 2004-04-08 2006-12-14 Wyeth Corp Ascorbato de bazedoxifeno como modulador del receptor de estrogeno selectivo.

Also Published As

Publication number Publication date
RU2007148071A (ru) 2009-08-10
BRPI0612586A2 (pt) 2010-11-23
TW200738283A (en) 2007-10-16
ECSP078057A (es) 2008-01-23
EP1898888A2 (en) 2008-03-19
CA2613102A1 (en) 2007-01-04
KR20080031037A (ko) 2008-04-07
RU2395286C2 (ru) 2010-07-27
PE20070188A1 (es) 2007-03-16
PA8684501A1 (es) 2007-01-17
US20070003623A1 (en) 2007-01-04
IL188223A0 (en) 2008-03-20
AU2006263638A1 (en) 2007-01-04
NO20080002L (no) 2008-03-12
WO2007002823A3 (en) 2007-08-09
JP2008545012A (ja) 2008-12-11
WO2007002823A2 (en) 2007-01-04
CR9597A (es) 2008-03-06
NI200700331A (es) 2009-02-16
CN101252921A (zh) 2008-08-27

Similar Documents

Publication Publication Date Title
ECSP078057A (es) Formulaciones de estrógenos conjugados y bazedoxifeno
EP1100522A4 (en) ADMINISTRATION OF ACTIVE AGENTS OVER THE LUNG
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
CO5140098A1 (es) Combinaciones de un agonista de betra-2 y un esteroide, su uso para tratamiento de enfermedades inflamatorias u obstructivas de las vias aereas
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
EE200300046A (et) Asabitsüklilised ühendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
EE05081B1 (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid
AR052221A1 (es) Metodo para el tratamiento de la enfermedad poliquistosis renal
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
MA31706B1 (fr) Formulations galéniques de composés organiques
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
BR0008509A (pt) Composição farmacêutica oral estabilizada contendo iodeto e iodato e método
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
SG152257A1 (en) Topical preparation containing ambroxol
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
AR065342A1 (es) Composiciones farmaceuticas que contienen fumarato de quetiapina
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
DK1225902T3 (da) Ciclesonidholdigt farmaceutisk præparat til administration til slimhinden
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
DE60137069D1 (de) Arzneizusammensetzungen enthaltend modafinilverbindungen
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones

Legal Events

Date Code Title Description
FB Suspension of granting procedure